25-OH-vitamin D has been demonstrated to have immunomodulatory effects in addition to maintaining calcium and bone homeostasis. Numerous autoimmune diseases have been linked to a deficiency in this nutrient. Immune cells can metabolize vitamin D and express the vitamin D nuclear receptor. In this study, we aimed to examine the relationship between vitamin D levels and adult patients newly diagnosed with ITP.

The methodology used for this investigation was retrospective. Our primary outcomes were the relationships between 25(OH)D value and platelet count as well as the clinical manifestations of ITP at the time of diagnosis and 25(OH)D value. We also looked at how the various factors and 25(OH)D levels correlated.

When the vitamin D levels of the patients included in the study were evaluated at the time of diagnosis of ITP; 15 (25%) had vitamin D sufficiency, 15 (25%) had vitamin D insufficiency, 30 (50%) had vitamin D deficiency. There was no statistically significant difference between the median ages of the patients in all 3 groups. In the group with sufficient vitamin D level, male gender was observed more than female gender (p:0.001).

When we compared the vitamin D levels of the patients according to their response to first-line treatment, no significant difference was found in terms of vitamin D levels in patients who did not respond to treatment, who responded partially, and who responded completely (p:0.32). Similarly, no significant difference was found between response to second-line treatment and vitamin D levels (p:0.16). There was no statistically significant difference in vitamin D between relapsed and non-relapsed